Harvard Bioscience Inc (HBIO)vsMedline Inc. Class A Common Stock (MDLN)
HBIO
Harvard Bioscience Inc
$6.20
-4.40%
HEALTHCARE · Cap: $27.94M
MDLN
Medline Inc. Class A Common Stock
$33.61
-2.44%
HEALTHCARE · Cap: $30.23B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 33970% more annual revenue ($29.14B vs $85.53M). MDLN leads profitability with a 3.3% profit margin vs -11.4%. MDLN earns a higher WallStSmart Score of 55/100 (C-).
HBIO
Avoid35
out of 100
Grade: F
MDLN
Buy55
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 1258.0% YoY
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -147.1% — below average capital efficiency
Revenue declined 4.7%
Premium valuation, high expectations priced in
Distress zone — elevated risk
3.3% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : HBIO
The strongest argument for HBIO centers on Price/Book. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bull Case : MDLN
The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.
Bear Case : HBIO
The primary concerns for HBIO are Market Cap, Piotroski F-Score, Return on Equity. Debt-to-equity of 4.39 is elevated, increasing financial risk.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
HBIO profiles as a turnaround stock while MDLN is a value play — different risk/reward profiles.
MDLN is growing revenue faster at 10.7% — sustainability is the question.
MDLN generates stronger free cash flow (316M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDLN scores higher overall (55/100 vs 35/100) and 10.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harvard Bioscience Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?